

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
21 October 2021 (21.10.2021)



(10) International Publication Number
WO 2021/209020 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) *A61P 35/00* (2006.01)
C07K 16/30 (2006.01) *C12N 15/13* (2006.01)
A61K 39/395 (2006.01)

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/CN2021/087617

(22) International Filing Date:

16 April 2021 (16.04.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

202010304381.8 17 April 2020 (17.04.2020) CN

(71) Applicant: **HUTCHISON MEDIPHARMA LIMITED**

[CN/CN]; Building 4, 720 Cailun Road, Pilot Free Trade Zone, Shanghai 201203 (CN).

(72) Inventors: **YANG, Yizhen**; Building 4, 720 Cailun Road, Pilot Free Trade Zone, Shanghai 201203 (CN). **CAI, Yu**; Building 4, 720 Cailun Road, Pilot Free Trade Zone, Shanghai 201203 (CN). **LI, Xiong**; Building 4, 720 Cailun Road, Pilot Free Trade Zone, Shanghai 201203 (CN). **ZHOU, Lei**; Building 4, 720 Cailun Road, Pilot Free Trade Zone, Shanghai 201203 (CN). **QING, Weiguo**; Building 4, 720 Cailun Road, Pilot Free Trade Zone, Shanghai 201203 (CN). **SU, Wei-Guo**; Building 4, 720 Cailun Road, Pilot Free Trade Zone, Shanghai 201203 (CN).

(74) Agent: **ZHONGZI LAW OFFICE**; 7F, New Era Building, 26 Pinganli Xidajie, Xicheng District, Beijing 100034 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: ANTI-OX40 ANTIBODY AND USES THEREOF

(57) Abstract: Provided are an anti-OX40 antibody or antigen-binding fragment thereof, a preparation method thereof and the use for treating OX40-related diseases or conditions.

WO 2021/209020 A1